Can You Take Semaglutide While Pregnant? The Evidence, Risks, and What to Do If You Conceive on Treatment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide is contraindicated during pregnancy based on animal studies showing skeletal malformations, growth restriction, and pregnancy loss at human-equivalent doses
• The medication requires a 2-month washout period before conception due to its 7-day half-life and cumulative tissue exposure
• If you discover pregnancy while on semaglutide, stop immediately and contact your provider, but understand that first-trimester exposure does not automatically predict harm
• No adequate human pregnancy data exists because pregnant patients are excluded from all GLP-1 clinical trials by design

Direct answer (40-60 words)

No. Semaglutide is contraindicated during pregnancy. Animal studies show dose-dependent fetal harm including skeletal malformations, growth restriction, and early pregnancy loss. The FDA classifies semaglutide as pregnancy category data insufficient, requiring discontinuation at least 2 months before planned conception. If pregnancy occurs during treatment, stop the medication immediately and contact your healthcare provider.

Table of contents

1. The regulatory answer and why it exists
2. What the animal studies actually show
3. The human data gap and why it matters
4. The 2-month washout protocol explained
5. What happens if you conceive while on semaglutide
6. The weight-and-pregnancy paradox most articles ignore
7. Comparing semaglutide to other diabetes medications in pregnancy
8. The FormBlends discontinuation protocol
9. What most articles get wrong about teratogenicity risk
10. When pregnancy is discovered: the decision tree
11. Breastfeeding and semaglutide
12. FAQ

The regulatory answer and why it exists

The FDA prescribing information for Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for weight management) states explicitly: "Discontinue Ozempic/Wegovy at least 2 months before a planned pregnancy due to the long washout period." The European Medicines Agency (EMA) provides identical guidance.

This recommendation exists because of three converging data points:

1. Animal reproductive toxicity studies showed harm. Rats and rabbits exposed to semaglutide during organogenesis (the period when fetal organs form) had increased rates of skeletal malformations, visceral abnormalities, and early pregnancy loss.

1. Semaglutide has a 7-day elimination half-life. After stopping treatment, the medication takes approximately 5 half-lives (35 days, or roughly 5 weeks) to clear from plasma. Tissue concentrations may persist longer.

1. Weight loss during pregnancy carries independent risks. Semaglutide's mechanism (reduced caloric intake, delayed gastric emptying, appetite suppression) can lead to inadequate maternal nutrition during critical fetal development windows.

The 2-month washout window is conservative by design. It accounts for the 5-week plasma clearance plus an additional 2 to 3 weeks to ensure tissue stores are eliminated and normal metabolic signaling resumes before conception.

Compounded semaglutide carries the same pregnancy contraindication as brand-name products. The active ingredient is identical, and the mechanism of action does not change based on formulation source.

What the animal studies actually show

The reproductive toxicity data comes from two phase 3 studies submitted to the FDA during semaglutide's approval process. The findings are dose-dependent and species-specific, but consistent across models.

Rat studies (Knudsen et al., Reproductive Toxicology 2018):

Pregnant rats received subcutaneous semaglutide at doses ranging from 0.03 mg/kg to 1.0 mg/kg daily during gestational days 6 through 17 (the period of organogenesis). Human-equivalent dosing for semaglutide 2.4 mg weekly in a 70 kg adult is approximately 0.034 mg/kg weekly, or 0.005 mg/kg daily.

Dose (mg/kg/day)	Human dose equivalent	Findings
0.03	~6x human dose	Increased early resorptions (pregnancy loss), reduced fetal weight
0.1	~20x human dose	Skeletal malformations (incomplete ossification of skull bones, vertebrae), visceral abnormalities
1.0	~200x human dose	Severe growth restriction, high resorption rate, structural heart defects in surviving fetuses

Rabbit studies (Knudsen et al., Reproductive Toxicology 2018):

Pregnant rabbits received semaglutide at 0.01 mg/kg to 0.5 mg/kg daily during gestational days 6 through 18.

Dose (mg/kg/day)	Human dose equivalent	Findings
0.01	~2x human dose	Increased early pregnancy loss, reduced fetal weight
0.1	~20x human dose	Skeletal abnormalities (fused ribs, bent limb bones), kidney malformations
0.5	~100x human dose	Nearly complete pregnancy loss, severe growth restriction in survivors

The pattern is consistent: semaglutide exposure during organogenesis causes structural malformations and growth restriction in a dose-dependent manner. The lowest doses showing harm are 2 to 6 times the human therapeutic dose, which is not a large safety margin in reproductive toxicology.

The mechanism is likely multifactorial. GLP-1 receptors are expressed in placental tissue, and semaglutide crosses the placenta in animal models. The medication may directly affect fetal GLP-1 signaling (which plays a role in pancreatic development) or indirectly harm the fetus through maternal malnutrition from reduced caloric intake.

The human data gap and why it matters

No randomized controlled trials of semaglutide in pregnant humans exist. Pregnancy is an automatic exclusion criterion in every GLP-1 agonist trial for ethical and regulatory reasons. The only human data comes from three sources:

1. Pregnancy exposure registries. Novo Nordisk maintains a voluntary registry for patients who became pregnant while on semaglutide. As of the most recent published summary (Novo Nordisk data on file, 2024), 214 pregnancies were reported. Outcomes included 89 live births, 62 elective terminations, 41 spontaneous abortions, and 22 ongoing pregnancies at time of report. Among live births, 6 infants had congenital anomalies (6.7%), compared to a 3% baseline rate in the general population.

1. Case reports. Scattered case reports describe individual pregnancies with semaglutide exposure. Most involve inadvertent first-trimester exposure followed by discontinuation. Outcomes are mixed: some normal births, some miscarriages, one case report of a neural tube defect (Pasternak et al., Journal of Clinical Endocrinology and Metabolism 2023).

1. Pharmacovigilance databases. The FDA Adverse Event Reporting System (FAERS) contains reports of semaglutide exposure during pregnancy, but these are uncontrolled, retrospective, and subject to reporting bias.

The registry data is the highest-quality human evidence available, and it suggests a signal. A 6.7% congenital anomaly rate is roughly double the background rate, but the sample size is small, exposure timing is inconsistent (some patients stopped at 4 weeks, others at 12 weeks), and there is no control group matched for baseline obesity and diabetes status.

This is the data gap: animal studies show clear harm, human data is sparse and uncontrolled, and no prospective study will ever be done for ethical reasons. Regulatory agencies default to the precautionary principle: assume animal findings translate to humans unless proven otherwise.

The 2-month washout protocol explained

Semaglutide has a plasma elimination half-life of approximately 7 days (165 hours). The standard pharmacokinetic rule is that a drug is considered eliminated after 5 half-lives, which for semaglutide is 35 days.

The FDA's 2-month (8-week) recommendation adds a safety buffer. Here's the timeline:

Timepoint	Event
Week 0	Last semaglutide injection
Week 1	50% of drug eliminated from plasma
Week 2	75% eliminated
Week 3	87.5% eliminated
Week 4	93.75% eliminated
Week 5	96.875% eliminated (considered clinically insignificant)
Week 6-8	Safety buffer for tissue clearance and metabolic normalization
Week 8+	Safe to conceive

The additional 2 to 3 weeks account for:

• Tissue-bound semaglutide (GLP-1 receptors in adipose tissue, pancreas, and gut may hold residual drug)
• Return of normal gastric emptying and appetite signaling
• Resumption of regular menstrual cycles (some patients experience cycle irregularities on GLP-1 agonists)
• Nutritional repletion after weight loss

The protocol is identical for compounded semaglutide. Half-life is determined by molecular structure, not formulation source.

What happens if you conceive while on semaglutide

Unplanned pregnancy during semaglutide treatment happens. Patients may not realize they are pregnant until 4 to 8 weeks of gestation, by which time organogenesis has begun. The clinical question becomes: what is the actual risk, and what should be done?

Step 1: Stop semaglutide immediately. Do not take another dose. The medication will clear over the next 5 weeks, but stopping prevents additional exposure.

Step 2: Contact your prescribing provider and OB/GYN. Report the exposure. Document the timing: last injection date, estimated conception date, and gestational age at discovery.

Step 3: Optimize nutrition. Semaglutide suppresses appetite. During early pregnancy, adequate caloric and micronutrient intake is critical. Work with a dietitian to ensure 300 to 500 additional calories per day, adequate protein (70 to 100 grams daily), and prenatal vitamins with folate.

Step 4: Enhanced fetal monitoring. Your OB/GYN may recommend:

• First-trimester ultrasound to confirm dating and viability
• Detailed anatomic ultrasound at 18 to 20 weeks to assess for structural abnormalities
• Possible fetal echocardiography if cardiac concerns arise (based on animal data showing heart defects at high doses)

Step 5: Enroll in the pregnancy exposure registry. Novo Nordisk maintains a registry to track outcomes. Participation is voluntary but helps build the human evidence base. Contact: 1-800-727-6500.

What the risk actually is: The baseline risk of congenital anomalies in the general population is 3%. The registry data suggests 6 to 7%, but this is confounded by obesity, diabetes, and other factors. The animal data shows harm at doses 2 to 6 times human exposure, but rodent organogenesis differs from human development.

A reasonable interpretation: first-trimester semaglutide exposure likely increases risk modestly, but the majority of pregnancies will result in normal outcomes. The exposure does not mandate termination, but it does warrant enhanced monitoring.

The weight-and-pregnancy paradox most articles ignore

Most articles on semaglutide and pregnancy focus exclusively on medication risk and ignore the baseline risk of obesity during pregnancy. This is a significant omission.

Maternal obesity (BMI ≥30) is independently associated with:

• Neural tube defects (2x increased risk)
• Congenital heart defects (1.3x increased risk)
• Gestational diabetes (4x increased risk)
• Preeclampsia (3x increased risk)
• Stillbirth (1.5x increased risk)
• Macrosomia and birth trauma

Women who start semaglutide typically have a BMI between 30 and 40. If semaglutide is stopped 2 months before conception and weight is regained during that washout period, the patient may conceive at a higher BMI than when they started treatment.

The paradox: stopping semaglutide to avoid fetal risk may increase fetal risk if significant weight regain occurs before conception.

The solution is not to continue semaglutide during pregnancy (the animal data is too concerning), but to implement a structured pre-conception plan:

1. Achieve target weight 4 to 6 months before planned conception. This allows time for semaglutide washout plus weight stabilization.
2. Transition to maintenance behaviors before stopping semaglutide. Build diet and exercise habits that can sustain weight without medication.
3. Consider metformin as a bridge. Metformin is pregnancy category B (safe in human studies) and can help maintain glycemic control and modest weight stability during the washout period. Discuss with your provider.
4. Work with a reproductive endocrinologist if you have PCOS or infertility. Weight loss from semaglutide can restore ovulation, but timing the washout with fertility treatment requires coordination.

This is the conversation most online articles skip: the risk calculus is not "semaglutide vs no semaglutide." It is "semaglutide exposure vs obesity-related pregnancy complications vs timing and planning."

Comparing semaglutide to other diabetes medications in pregnancy

Patients on semaglutide for type 2 diabetes face a different question: what diabetes medication is safe during pregnancy?

Medication	Pregnancy category	Safety data	Typical use in pregnancy
Insulin (all forms)	B	Extensive human data, no increased risk	First-line for diabetes in pregnancy
Metformin	B	Large human studies, safe in pregnancy	Commonly used for PCOS and gestational diabetes
Glyburide	B (but controversial)	Some human data, possible neonatal hypoglycemia	Second-line, less preferred than insulin
Semaglutide	Insufficient data, animal harm	No adequate human data, animal studies show fetal harm	Contraindicated, stop 2 months before conception
Tirzepatide	Insufficient data, animal harm	Similar to semaglutide	Contraindicated
Liraglutide	Insufficient data, animal harm	Limited human data, animal studies show harm	Contraindicated

The standard of care for diabetes management during pregnancy is insulin. It does not cross the placenta, has decades of safety data, and provides precise glycemic control.

The transition protocol for patients on semaglutide for diabetes:

1. 8 to 12 weeks before planned conception: Stop semaglutide, start basal insulin (typically glargine or detemir) plus short-acting insulin with meals if needed.
2. Continue metformin if already prescribed. Metformin is safe in pregnancy and can reduce insulin requirements.
3. Achieve HbA1c <6.5% before conception. Elevated glucose during organogenesis increases risk of congenital heart defects and neural tube defects.
4. Work with a maternal-fetal medicine specialist. High-risk pregnancy care is appropriate for pre-existing diabetes.

For patients on semaglutide for weight loss only (no diabetes), no replacement medication is needed during pregnancy. Weight loss is not a goal during pregnancy. Weight stability or modest gain (15 to 25 pounds for overweight patients, 11 to 20 pounds for obese patients per ACOG guidelines) is the target.

The FormBlends discontinuation protocol

When a FormBlends patient planning pregnancy notifies us, we follow a structured discontinuation protocol. This is the pattern we see work across several hundred planned discontinuations:

Phase 1: Assessment (Week 0)

• Confirm pregnancy planning timeline (trying now vs 3 months vs 6 months)
• Document current dose, duration of treatment, and total weight lost
• Assess for diabetes: if HbA1c >5.7%, coordinate with endocrinology for insulin transition
• Review baseline eating patterns and whether weight-maintaining behaviors are established

Phase 2: Maintenance dose hold (Weeks 1-4)

• If patient is on escalating doses, hold at current dose for 4 weeks to stabilize weight
• Focus on behavioral reinforcement: meal structure, portion awareness, movement habits
• Address psychological preparation for stopping medication

Phase 3: Discontinuation (Week 4)

• Administer final dose
• Provide written timeline: "Safe to conceive after [specific date 8 weeks from now]"
• Schedule 2-week and 6-week follow-up check-ins

Phase 4: Washout monitoring (Weeks 5-8)

• Monitor weight weekly (expect 2 to 5 pounds regain from glycogen and water, not fat)
• If weight regain exceeds 1 pound per week, intensify behavioral support
• Confirm return of normal menstrual cycles
• Optimize prenatal nutrition: folate 400 to 800 mcg daily, adequate protein and iron

Phase 5: Conception clearance (Week 8+)

• Confirm clearance to conceive
• Provide OB/GYN with documentation of last semaglutide dose and washout completion
• Enroll patient in pregnancy exposure registry if conception occurs

The protocol is identical for compounded and brand-name semaglutide. The timeline is driven by pharmacokinetics, not formulation.

What most articles get wrong about teratogenicity risk

Most articles on semaglutide and pregnancy make one of two errors:

Error 1: Overstating certainty of harm. Headlines like "Ozempic causes birth defects" misrepresent the evidence. The animal studies show harm at supratherapeutic doses. The human registry data shows a possible signal but is confounded and underpowered. Saying "semaglutide causes birth defects" is not supported. Saying "semaglutide is contraindicated in pregnancy due to animal data and insufficient human safety evidence" is accurate.

Error 2: Ignoring dose and timing. Teratogenic risk is both dose-dependent and timing-dependent. The critical window for most structural malformations is gestational weeks 3 through 8 (organogenesis). Exposure before conception or after week 12 carries different risk than exposure during organogenesis.

A patient who stops semaglutide at 4 weeks of pregnancy (2 weeks after missed period) has had 4 weeks of first-trimester exposure during early organogenesis. A patient who stops 8 weeks before conception has zero fetal exposure. These are not equivalent risks, but most articles treat all "semaglutide and pregnancy" scenarios identically.

The animal data also shows dose-dependence. Harm occurs at 2x to 6x human doses. A patient on semaglutide 0.5 mg weekly (the starting dose for diabetes) has lower exposure than a patient on 2.4 mg weekly (the maintenance dose for weight loss). Again, most articles ignore this.

The accurate framing: semaglutide is contraindicated in pregnancy because animal studies show fetal harm at doses near human therapeutic levels, and no adequate human data exists to rule out risk. The magnitude of risk in humans is unknown. The risk is likely highest during organogenesis (weeks 3 to 8) and at higher doses.

When pregnancy is discovered: the decision tree

If you discover pregnancy while on semaglutide, follow this decision tree:

Step 1: Confirm pregnancy.

• Home pregnancy test positive → confirm with provider and dating ultrasound
• Document last menstrual period and estimated conception date

Step 2: Document semaglutide exposure.

• Last injection date
• Dose and frequency
• Total duration of treatment
• Estimated gestational age at last dose

Step 3: Stop semaglutide immediately.

• Do not take another dose
• Medication will clear over 5 weeks

Step 4: Risk stratification based on timing.

Scenario	Exposure window	Recommended action
Last dose before conception	No fetal exposure	Standard prenatal care, no additional monitoring needed
Last dose 0-4 weeks gestation	Pre-organogenesis or early organogenesis	Enhanced monitoring: detailed anatomy scan at 18-20 weeks, consider fetal echo
Last dose 5-12 weeks gestation	Peak organogenesis	High-risk OB referral, detailed anatomy scan, fetal echo, possible genetic counseling
Last dose >12 weeks gestation	Post-organogenesis	Enhanced growth monitoring (GLP-1 may affect fetal growth), otherwise standard care

Step 5: Optimize nutrition immediately.

• Increase caloric intake to pregnancy requirements (add 300-500 calories/day)
• Ensure adequate protein (70-100 g/day)
• Start or continue prenatal vitamins with folate

Step 6: Coordinate care.

• Notify OB/GYN of exposure
• Enroll in Novo Nordisk pregnancy registry (1-800-727-6500)
• If you have diabetes, transition to insulin with endocrinology

Step 7: Enhanced fetal monitoring.

• First-trimester ultrasound to confirm viability and dating
• Detailed anatomic survey at 18-20 weeks (standard is basic anatomy scan; request detailed/level II)
• Fetal echocardiography at 20-22 weeks if exposure occurred during weeks 5-8 (cardiac organogenesis window)
• Serial growth scans in third trimester if growth restriction is suspected

Step 8: Document outcomes.

• Report pregnancy outcome to registry (helps build human evidence base)
• Provide outcome data to prescribing provider

The decision tree is the same for compounded semaglutide. The active pharmaceutical ingredient and mechanism are identical.

Breastfeeding and semaglutide

Semaglutide's safety during breastfeeding is also unknown. The prescribing information states: "It is not known whether semaglutide is present in human milk, affects milk production, or has effects on the breastfed infant."

Animal studies show semaglutide is present in the milk of lactating rats at low concentrations (approximately 3 to 12 times lower than maternal plasma levels). Whether this translates to human breast milk is unknown.

The theoretical concerns:

1. GLP-1 receptors are present in neonatal pancreas and gut. Exposure to exogenous GLP-1 agonists could theoretically affect infant glucose regulation or gut development.
2. Semaglutide suppresses appetite. If present in breast milk and active in the infant, it could reduce feeding and cause inadequate weight gain.
3. Maternal weight loss during breastfeeding may reduce milk supply. Rapid maternal weight loss (more than 1 pound per week) is associated with decreased milk production.

The conservative recommendation: avoid semaglutide during breastfeeding. If weight management is needed postpartum, delay semaglutide until after weaning or use alternatives compatible with breastfeeding (metformin is considered safe, appears in breast milk at low levels, and has no known adverse effects on breastfed infants per LactMed database).

If a patient chooses to use semaglutide while breastfeeding despite the unknown risk, close monitoring of infant weight gain and feeding patterns is warranted.

FAQ

Can you take semaglutide while pregnant? No. Semaglutide is contraindicated during pregnancy. Animal studies show fetal harm including skeletal malformations and growth restriction. No adequate human safety data exists. The medication must be stopped at least 2 months before planned conception.

What happens if I get pregnant while on semaglutide? Stop the medication immediately and contact your healthcare provider. Document the exposure timing and enroll in the pregnancy registry. Most pregnancies with first-trimester exposure result in normal outcomes, but enhanced fetal monitoring is recommended.

How long after stopping semaglutide can I get pregnant? Wait at least 8 weeks (2 months) after your last dose. Semaglutide has a 7-day half-life and takes 5 weeks to clear from plasma. The additional 2 to 3 weeks allow for tissue clearance and metabolic normalization.

Does semaglutide cause birth defects? Animal studies show structural malformations at doses 2 to 6 times human therapeutic levels. Human data is limited to small registries showing a possible increased risk, but the data is confounded. The medication is contraindicated due to animal findings and lack of adequate human safety data.

Can I take Ozempic during pregnancy if I have diabetes? No. Ozempic (semaglutide) is contraindicated in pregnancy. The standard of care for diabetes during pregnancy is insulin, which does not cross the placenta and has extensive safety data. Transition to insulin at least 2 months before planned conception.

Is compounded semaglutide safer than Ozempic during pregnancy? No. Compounded semaglutide contains the same active ingredient and carries the same pregnancy contraindication. The risk is determined by the medication's mechanism, not the formulation source.

What if I didn't know I was pregnant and took semaglutide for 6 weeks? Stop immediately. Contact your OB/GYN and document the exposure. Six weeks of exposure includes early organogenesis, so enhanced monitoring (detailed anatomy scan, possible fetal echocardiography) is appropriate. Most exposures do not result in harm, but monitoring is warranted.

Can semaglutide affect fertility? Semaglutide can improve fertility in patients with PCOS by promoting weight loss and restoring ovulation. This means pregnancy can occur unexpectedly. Use reliable contraception while on semaglutide if you are not planning pregnancy.

Should I stop semaglutide if I'm trying to get pregnant in 6 months? Yes. Stop 2 months before you plan to start trying. Use the intervening 4 months to achieve target weight and establish weight-maintaining behaviors. Consider metformin as a bridge if you need glycemic support during washout.

Can I breastfeed while taking semaglutide? It is unknown whether semaglutide passes into human breast milk or affects breastfed infants. The conservative recommendation is to avoid semaglutide during breastfeeding. Alternatives like metformin are considered compatible with breastfeeding.

What diabetes medication is safe during pregnancy? Insulin is the first-line treatment for diabetes during pregnancy. It does not cross the placenta and has decades of safety data. Metformin is also used and considered safe based on large human studies.

Will I gain weight back after stopping semaglutide before pregnancy? Some weight regain (2 to 5 pounds) from glycogen and water is normal. Fat regain depends on whether weight-maintaining behaviors are established. Work with a dietitian during the washout period to minimize regain while ensuring adequate nutrition for conception.

Sources

1. Knudsen LB et al. Reproductive toxicology studies with semaglutide in rats and rabbits. Reproductive Toxicology. 2018.
2. Novo Nordisk. Ozempic (semaglutide) prescribing information. FDA-approved labeling. 2024.
3. Novo Nordisk. Wegovy (semaglutide) prescribing information. FDA-approved labeling. 2024.
4. Novo Nordisk. Pregnancy exposure registry data on file. 2024.
5. Pasternak Y et al. Case report: Neural tube defect following first-trimester semaglutide exposure. Journal of Clinical Endocrinology and Metabolism. 2023.
6. American College of Obstetricians and Gynecologists. Weight gain during pregnancy. Committee Opinion No. 548. 2013.
7. Stothard KJ et al. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA. 2009.
8. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
9. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
11. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
12. National Library of Medicine. LactMed database: Drugs and Lactation Database. 2024.
13. Holt RIG et al. The management of type 1 and type 2 diabetes in pregnancy. Diabetic Medicine. 2021.
14. European Medicines Agency. Ozempic assessment report. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.